MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 207164 | Name: RBN012759
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RBN012759 is a potent and selective PARP14 inhibitor which decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. RBN012759 inhibits PARP14 with a biochemical half-maximal inhibitory concentration of 0.003 μM, exhibits >300-fold selectivity over all PARP family members, and its profile enables further study of PARP14 biology and disease association both in vitro and in vivo. Inhibition of PARP14 with RBN012759 reverses IL-4-driven protumor gene expression in macrophages and induces an inflammatory mRNA signature similar to that induced by immune checkpoint inhibitor therapy in primary human tumor explants.

Chemical Structure

RBN012759
RBN012759
CAS#2360851-29-0

Theoretical Analysis

MedKoo Cat#: 207164

Name: RBN012759

CAS#: 2360851-29-0

Chemical Formula: C19H23FN2O3S

Exact Mass: 378.1413

Molecular Weight: 378.46

Elemental Analysis: C, 60.30; H, 6.13; F, 5.02; N, 7.40; O, 12.68; S, 8.47

Price and Availability

Size Price Availability Quantity
1mg USD 90.00 Ready to ship
5mg USD 250.00 Ready to ship
10mg USD 450.00 Ready to ship
25mg USD 750.00 Ready to ship
50mg USD 1,250.00 Ready to ship
100mg USD 1,950.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RBN012759; RBN-012759; RBN 012759;
IUPAC/Chemical Name
7-(cyclopropylmethoxy)-5-fluoro-2-((((1r,4r)-4-hydroxycyclohexyl)thio)methyl)quinazolin-4(3H)-one
InChi Key
NKZDEFKPZSLQRF-MQMHXKEQSA-N
InChi Code
InChI=1S/C19H23FN2O3S/c20-15-7-13(25-9-11-1-2-11)8-16-18(15)19(24)22-17(21-16)10-26-14-5-3-12(23)4-6-14/h7-8,11-12,14,23H,1-6,9-10H2,(H,21,22,24)/t12-,14-
SMILES Code
O=C1NC(CS[C@H]2CC[C@H](O)CC2)=NC3=C1C(F)=CC(OCC4CC4)=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
PARP14 has been implicated by genetic knockout studies to promote protumor macrophage polarization and suppress the antitumor inflammatory response due to its role in modulating interleukin-4 (IL-4) and interferon-γ signaling pathways.
Biological target:
RBN012759 is a selective inhibitor of PARP14, with an IC50 of <3 nM. RBN012759 displays 300-fold selectivity over the monoPARPs and 1000-fold selectivity over the polyPARPs.
In vitro activity:
The ability of RBN012759 to inhibit PARP14-specific self-MARylation was evaluated. MARylation was detected by immunoblot using an antibody that binds to both MAR and PAR and a PARP14 antibody in IFN-γ-stimulated primary human macrophages. RBN012759 decreased the MAR/PAR signal corresponding to PARP14-self-MARylation in a concentration-dependent manner, further supporting its activity on endogenous PARP14. To reinforce the specificity of PARP14 autoMARylation, the CFPAC-1 cell line was used due to its high endogenous PARP14 baseline level and response to IFN-γ stimulation by increasing PARP14 and ADP-ribosylation. First, endogenous PARP14 was immunoprecipitated from IFN-γ-stimulated CFPAC-1 cells and probed for MAR/PAR. These data demonstrated that PARP14 auto-MARylation is stimulated by IFN-γ and robustly inhibited by RBN012759. In addition, CFPAC-1 cells were stimulated with IFN-γ to increase PARP14 expression and MARylation and treated with increasing concentrations of RBN012759. RBN012759 decreased the MARylation signal in a concentration-dependent manner, similar to that observed in human macrophages. Reference: ell Chem Biol. 2021 Aug 19;28(8):1158-1168.e13. https://pubmed.ncbi.nlm.nih.gov/33705687/
In vivo activity:
The ability of RBN012759 to engage PARP14 in vivo was also evaluated. C57BL/6 mice were treated with RBN012759 at 300 and 500 mg/kg BID PO for 7 days, during which it was well tolerated with no significant body weight loss observed. Treatment with RBN012759 led to an increase in PARP14 protein in vivo. The 500 mg/kg treatment group showed increased PARP14 protein, while the 300 mg/kg group did not, correlating with RBN012759 plasma exposures at the 12 h time point in which the mouse PARP14-free IC50 value was increased by 6- and <1-fold, respectively. These data support the use of RBN012759 as an in vivo chemical probe that selectively engages PARP14 in tissue. Reference: ell Chem Biol. 2021 Aug 19;28(8):1158-1168.e13. https://pubmed.ncbi.nlm.nih.gov/33705687/
Solvent mg/mL mM
Solubility
DMSO 163.0 431.06
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 378.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Schenkel LB, Molina JR, Swinger KK, Abo R, Blackwell DJ, Lu AZ, Cheung AE, Church WD, Kunii K, Kuplast-Barr KG, Majer CR, Minissale E, Mo JR, Niepel M, Reik C, Ren Y, Vasbinder MM, Wigle TJ, Richon VM, Keilhack H, Kuntz KW. A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. Cell Chem Biol. 2021 Aug 19;28(8):1158-1168.e13. doi: 10.1016/j.chembiol.2021.02.010. Epub 2021 Mar 10. PMID: 33705687.
In vitro protocol:
1. Schenkel LB, Molina JR, Swinger KK, Abo R, Blackwell DJ, Lu AZ, Cheung AE, Church WD, Kunii K, Kuplast-Barr KG, Majer CR, Minissale E, Mo JR, Niepel M, Reik C, Ren Y, Vasbinder MM, Wigle TJ, Richon VM, Keilhack H, Kuntz KW. A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. Cell Chem Biol. 2021 Aug 19;28(8):1158-1168.e13. doi: 10.1016/j.chembiol.2021.02.010. Epub 2021 Mar 10. PMID: 33705687.
In vivo protocol:
1. Schenkel LB, Molina JR, Swinger KK, Abo R, Blackwell DJ, Lu AZ, Cheung AE, Church WD, Kunii K, Kuplast-Barr KG, Majer CR, Minissale E, Mo JR, Niepel M, Reik C, Ren Y, Vasbinder MM, Wigle TJ, Richon VM, Keilhack H, Kuntz KW. A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. Cell Chem Biol. 2021 Aug 19;28(8):1158-1168.e13. doi: 10.1016/j.chembiol.2021.02.010. Epub 2021 Mar 10. PMID: 33705687.
Schenkel LB, Molina JR, Swinger KK, Abo R, Blackwell DJ, Lu AZ, Cheung AE, Church WD, Kunii K, Kuplast-Barr KG, Majer CR, Minissale E, Mo JR, Niepel M, Reik C, Ren Y, Vasbinder MM, Wigle TJ, Richon VM, Keilhack H, Kuntz KW. A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. Cell Chem Biol. 2021 Aug 19;28(8):1158-1168.e13. doi: 10.1016/j.chembiol.2021.02.010. Epub 2021 Mar 10. PMID: 33705687.